What PHARMA JAPAN does

PHARMA JAPAN is an English-language subscription news service covering Japan's pharmaceutical industry, operated by JIHO, Inc., a Japanese media company headquartered in Chiyoda-ku, Tokyo. The service was launched in 2001 to translate and repackage content from Nikkan Yakugyo, JIHO's flagship Japanese-language pharma trade journal, addressing a documented gap in authoritative English-language coverage of Japan's drug pricing, regulatory, and reimbursement landscape.

The product is a single subscription-based digital publication delivered via the website pj.jiho.jp, organized into editorial categories (Regulatory, Business, Organization, Academia, Commentary, Column, Trends, Feature, Interview, Lexicon). Coverage spans Chuikyo drug pricing reforms, MHLW safety actions, FDA/Japan regulatory interaction, M&A activity, regenerative medicine policy, and clinical development, including exclusive interviews with top regulatory officials. An eBook format accessible via Adobe Reader is available to subscribers as an additional consumption surface.

Monetization is purely subscription-based. Annual full subscriber access is priced at 180,000 yen per ID (excluding tax), with a 6-month option at 94,800 yen and volume discounts offered for 5+ user corporate packages via inquiry. A 2-week free trial and a free "Today's Headlines" daily email digest serve as top-of-funnel acquisition channels. The publication is targeted at pharmaceutical executives, regulatory affairs specialists, R&D personnel, and business development leaders working in or with interest in Japan's pharma sector, including English-speaking professionals outside Japan. Headcount is approximately 6 employees, consistent with a lean editorial operation.

Name

PHARMA JAPAN

Legal name

JIHO, Inc.

Website

https://pj.jiho.jp

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1–10 employees

Short description

PHARMA JAPAN is an English-language subscription news service covering Japan's pharmaceutical industry, operated by JIHO, Inc. It translates content from Nikkan Yakugyo and serves pharmaceutical executives, regulatory affairs specialists, and R&D leaders needing English coverage of Japan's drug pricing, regulatory, and reimbursement landscape.

Ownership category

akta.pro rank

GTM type

B2B

Offering type

Digital Commerce or Content

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Subscription Revenue: PHARMA JAPAN generates revenue primarily through paid subscriptions. Full Subscriber plans are offered at 180,000 yen per ID per year (excluding tax) or 94,800 yen for 6 months. Volume discounts are available for 5 or more users under combined billing. Free tiers include a 2-week trial and a no-cost Today's Headlines email notice.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

PHARMA JAPAN is an English-language subscription news service covering Japan's pharmaceutical industry, providing in-depth reporting on drug pricing, regulatory decisions (MHLW, Chuikyo), R&D trends, M&A, and pharmaceutical policymaking. All content is translated from Nikkan Yakugyo, a leading Japanese-language pharma trade journal also operated by JIHO, Inc. The publication is sold via paid subscriptions (Full Subscriber plans) with a free 2-week trial and a complimentary Today's Headlines email digest.

Product overview

PHARMA JAPAN is a single subscription-based English-language news publication covering Japan's pharmaceutical industry. The service provides regulatory, business, and R&D news, drug pricing updates, and pharmaceutical policymaking coverage, including exclusive interviews with top regulatory officials and pharma executives. Content is sourced from Nikkan Yakugyo and offered through tiered subscriptions (Full Subscriber, Trial Subscriber, and Today's Headlines Subscriber).

Differentiator

Problem solved

Functional benefit

Products and services

• PHARMA JAPAN Subscription News Service English-language subscription news service providing coverage of Japan's pharmaceutical industry, including regulatory decisions, drug pricing and reimbursement policy, R&D trends, M&A activity, and industry developments. All content is translated from Nikkan Yakugyo and accessible via the pj.jiho.jp website through authenticated subscriber login.
• Today's Headlines Email Digest Free email notification service delivering daily pharmaceutical industry headlines and weekly news rankings from Japan to subscribers.
• PHARMA JAPAN eBook Subscriber-only eBook format of the PHARMA JAPAN publication, accessible via Adobe Reader through the website for full subscribers.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered minor.

• Kyorin PharmaceuticalminorChannel Partner/ Reseller/ DistributorSanten Pharmaceutical and Kyorin Pharmaceutical entered a co-promotion agreement in Japan for Alesion Eyelid Cream 0.5% (epinastine), a long-acting treatment for allergic conjunctivitis. Under the pact, Kyorin began promoting the product to targeted physicians. This is a co-promotion arrangement within the Japanese pharmaceutical market.
• Daiichi SankyominorStrategic or Co-development PartnerFRONTEO built an AI prediction model with Daiichi Sankyo that automatically extracts toxicological interpretations from Standard for Exchange of Nonclinical Data (SEND) datasets and toxicity study reports. The model is powered by FRONTEO's AI technology. This is a co-development arrangement for an AI-driven drug discovery tool.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Endpoints News: Subscription-supported B2B news outlet covering biotech and pharma R&D, business, and policy. Comparable as a paid trade publication serving pharma/biotech industry professionals.
• Scrip (Citeline, Informa): Pharma industry intelligence publication covering business, R&D, and policy globally under Informa's Citeline. Comparable business model (paid B2B pharma news/intelligence) and overlapping audience of pharma executives.
• FiercePharma: B2B pharma industry news outlet covering drug commercialization, regulatory, and policy. Comparable as a trade news brand serving pharma executives and industry professionals, though US-centric.
• BioCentury: Subscription-based B2B intelligence publication covering biotech strategy, R&D, and policy. Comparable as a paid trade intelligence service for pharma/biotech industry professionals.
• Pharmaceutical Technology: B2B trade publication covering pharmaceutical manufacturing, R&D, and regulation. Comparable as a paid trade media brand serving pharma industry professionals with regulatory and business coverage.
• The Pharma Letter: Subscription-based B2B pharmaceutical trade publication covering global drug development, regulation, and pricing. Most comparable as a paid trade-news service targeting pharma professionals, though with broader global scope rather than Japan-specific focus.
• Pink Sheet (Citeline, Informa): Long-running pharma regulatory and policy intelligence publication, now part of Informa's Citeline. Directly comparable as a paid pharma regulatory/policy intelligence service for industry professionals.

Broad incumbents

• Informa Pharma Intelligence: Large incumbent pharma intelligence portfolio (parent of Pink Sheet, Scrip, Citeline, Trialtrove). Comparable as a broad pharma intelligence offering, but at significantly larger scale and broader scope than PHARMA JAPAN's Japan-focused niche.

Others

• Pharma Japan (Jiho English) parent: JIHO / Nikkan Yakugyo: Nikkan Yakugyo, the Japanese-language sister publication from JIHO, Inc., is the underlying content source for PHARMA JAPAN. Included as an ecosystem participant rather than a true external peer — illustrates the content-pipeline relationship.

Emerging players

• DIA Global Forum: Regulatory-focused publication from the Drug Information Association covering global drug development and regulatory science. Comparable as a specialized pharma regulatory publication serving industry professionals, though distributed via association membership.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pharma-japan

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PHARMA JAPAN